Adar Poonawalla in the NRC Handelsblad - Bilthoven Biologicals

Back to the overview

At Bilthoven Biologicals we are very proud to be a part of the Cyrus Poonawalla Group. Thanks to the efforts of the Serum Institute and Mr. Adar Poonawalla hopefully soon there will be a COVID-19 vaccine to bring to low- and middle income countries and beyond by the Serum Institute of India.

Here you can read the interview (Dutch)

More News

In Memoriam: Ad van den Biggelaar

It is with deep sadness that we share the news of the passing of Ad van den Biggelaar, COO at Bithoven Biologicals (BBio). Ad was a beloved colleague, whose legacy and influence within our company are undeniable.

European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe

SIILTIBCY® is a tuberculosis skin test approved in European Union that detects tuberculosis infection regardless of BCG vaccination status with demonstrated sensitivity and specificity.

Bilthoven Biologicals opens Pandemic Preparedness Vaccine Facilities

The new state-of-the-art facilities have received approval from European Commission EU FAB and ensures vaccine accessibility for Europe in the event of a pandemic situation.